Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

导出原文传递

翻译打印收藏纠错

作者： Mahaffey, Kenneth W. ^[1] ; Neal, Bruce ^[2] ; Perkovic, Vlado ^[3] ; de Zeeuw, Dick ^[4] ; Fulcher, Greg ^[5] ; Erondu, Ngozi ^[6] ; Shaw, Wayne ^[7] ; Sun, Tao ^[8] ; Desai, Mehul ^[9] ; Matthews, David R.

作者单位： Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands ^[1] Royal North Shore Hosp, Med, Sydney, NSW, Australia ^[2] Stanford Univ, Sch Med, Dept Med, Stanford Ctr Clin Res, Stanford, CA 94305 USA ^[3] Janssen Res & Dev LLC, RA CVM Metab, Raritan, NJ USA ^[4] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England ^[5] Janssen Res & Dev LLC, Clin Biostat, Raritan, NJ USA ^[6] Janssen Res & Dev LLC, SH CVM Metab, Raritan, NJ USA ^[7] George Inst Global Hlth, Food Policy Div, Sydney, NSW, Australia ^[8] George Inst Global Hlth, Med, Sydney, NSW, Australia ^[9]

关键词 canagliflozin type 2 diabetes primary vs secondary prevention

发布时间 2021-01-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交